Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 2/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.34 |
| ▸ | CD38 | P28907 | 4/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EEF2K | O00418 | 2/20 | 0.31 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17874008 | 0.75 | RET (0.46) | POLBRAB9ASMN1; SMN2GAA | |
| SCHEMBL5904803 | 0.73 | DYRK1A (0.37) | IMPDH2PRMT5WDR77 | |
| SCHEMBL3990124 | 0.70 | CHUK (0.47) | CHEK2RAB9ASMN1; SMN2 | |
| SCHEMBL3981490 | 0.69 | SMN1; SMN2 (0.46) | POLBRAB9ASMN1; SMN2 | |
| SCHEMBL3989188 | 0.69 | LMNA (0.51) | POLBRAB9ASMN1; SMN2 | |
| SCHEMBL15774608 | 0.69 | HSD17B1 (0.47) | POLBRAB9ASMN1; SMN2GAA | |
| SCHEMBL6872027 | 0.69 | CYP2E1 (0.57) | RAB9ASMN1; SMN2 | |
| SCHEMBL31301171 | 0.69 | MYC (0.40) | MYCCHEK2LRRK2SCDSCD5 | |
| SCHEMBL3987343 | 0.68 | RAB9A (0.55) | POLBRAB9ASMN1; SMN2 | |
| SCHEMBL3987365 | 0.68 | MAPT (0.49) | RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002487-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002487-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CGAS, TDP1, CYP11B2 | MYC 2570/4885CHEK1 35/4885CHEK2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.